Wordt geladen...
Longer Control of Nivolumab in Metastatic Renal Cell Carcinoma Patients with End-Stage Kidney Disease on Dialysis
INTRODUCTION: Nivolumab has been introduced for metastatic renal cell carcinoma (mRCC) as a second-line therapy for years. However, despite widespread evidence of its utility, few reports have described the efficacy of nivolumab for mRCC patients on hemodialysis. CASE PRESENTATION: A 68-year-old man...
Bewaard in:
| Gepubliceerd in: | Case Rep Oncol |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
S. Karger AG
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6738248/ https://ncbi.nlm.nih.gov/pubmed/31543776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000501768 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|